glp 1 kidney protection GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic disease GLP-1 Receptor Agonists and Kidney

Outcomes included changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), end-systolic volume (LVESV), global longitudinal strain (GLS), left ventricular mass, left atrial volume (LAV), and NT-proBNP levels

1000 (GRAS)

Although relatively small in size, GHK-Cu has attracted significant scientific interest because of its ability to influence hundreds or even thousands of genes involved in tissue repair, inflammation, antioxidant protection, cellular regeneration, and wound healing

Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals